retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide, a (GLP1, GIP, glucagon), just released trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide is gaining attention in

doi:10.4093/joms.2025.34.1.22

However, outside of a labour-intensive clinical trial setting, long-term weight loss is notoriously difficult to achieve [3, 4]

Here are a few key things I encourage clients to prioritize: Protein First Protein helps preserve lean muscle mass during weight loss and supports fullness and stable energy

Understanding GLP-1 Medications Both tirzepatide and semaglutide belong to a class of medications called GLP-1 receptor agonists, but theres an important distinction that makes tirzepatide potentially more effective for some patients

Rapid Commun Mass Spectrom 34: e8849

Others apply it specifically to sub-milligram doses that require compounded formulations